Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. - Enterprise Valueverified

OTLK

Price:

$1.58

Market Cap:

$65.00M

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Hua...[Read more]

Industry

Biotechnology

IPO Date

2016-06-14

Stock Exchange

NASDAQ

Ticker

OTLK

The Enterprise Value as of June 2026 (TTM) for Outlook Therapeutics, Inc. (OTLK) is 84.44M

According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 84.44M. This represents a change of 11.27% compared to the average of 75.89M of the last 4 quarters.

Outlook Therapeutics, Inc. (OTLK) Historical Enterprise Value (quarterly & annually)

How has OTLK Enterprise Value performed in the past?

The mean historical Enterprise Value of Outlook Therapeutics, Inc. over the last ten years is 106.40M. The current 84.44M Enterprise Value has changed 7.84% with respect to the historical average. Over the past ten years (40 quarters), OTLK's Enterprise Value was at its highest in in the June 2023 quarter at 448.00M. The Enterprise Value was at its lowest in in the December 2019 quarter at 30.90M.

Quarterly (TTM)
Annual

Average

106.40M

Median

63.22M

Minimum

34.04M

Maximum

328.73M

Outlook Therapeutics, Inc. (OTLK) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Outlook Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 577.77%

Maximum Annual Enterprise Value = 328.73M

Minimum Annual Increase = -73.27%

Minimum Annual Enterprise Value = 34.04M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202559.00M-48.19%
2024113.86M68.81%
202367.45M-73.27%
2022252.30M-23.25%
2021328.73M577.77%
202048.50M42.50%
201934.04M-23.27%
201844.36M-7.85%
201748.14M-28.76%
201667.58M-12.24%

Outlook Therapeutics, Inc. (OTLK) Average Enterprise Value

How has OTLK Enterprise Value performed in the past?

The current Enterprise Value of Outlook Therapeutics, Inc. (OTLK) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

80.10M

5-year avg

164.27M

10-year avg

106.40M

Outlook Therapeutics, Inc. (OTLK) Enterprise Value vs. Peers

How is OTLK’s Enterprise Value compared to its peers?

Outlook Therapeutics, Inc.’s Enterprise Value is greater than Spruce Biosciences, Inc. (24.88M), greater than NRx Pharmaceuticals, Inc. (62.85M), greater than Cue Biopharma, Inc. (61.85M), greater than Werewolf Therapeutics, Inc. (8.27M), greater than IO Biotech, Inc. (-28323310.00), less than OS Therapies Incorporated (511.35M), greater than Coeptis Therapeutics, Inc. (52.23M), greater than Equillium, Inc. (47.71M), less than Century Therapeutics, Inc. (195.22M), greater than Medicus Pharma Ltd. Common Stock (3.89M),

Build a custom stock screener for Outlook Therapeutics, Inc. (OTLK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Outlook Therapeutics, Inc. (OTLK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Outlook Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Outlook Therapeutics, Inc. (OTLK)?

What is the 3-year average Enterprise Value for Outlook Therapeutics, Inc. (OTLK)?

What is the 5-year average Enterprise Value for Outlook Therapeutics, Inc. (OTLK)?

How does the current Enterprise Value for Outlook Therapeutics, Inc. (OTLK) compare to its historical average?